- Home
- OSTX vs ACRV Comparison
OSTX vs ACRV Comparison
Compare OSTX & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OSTX
- ACRV
- Stock Information
- Founded
- OSTX 2018
- ACRV 2018
- Country
- OSTX United States
- ACRV United States
- Employees
- OSTX N/A
- ACRV N/A
- Industry
- OSTX
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- OSTX
- ACRV Health Care
- Exchange
- OSTX NYSE
- ACRV Nasdaq
- Market Cap
- OSTX 43.0M
- ACRV 40.4M
- IPO Year
- OSTX 2024
- ACRV 2022
- Fundamental
- Price
- OSTX $1.76
- ACRV $1.38
- Analyst Decision
- OSTX Strong Buy
- ACRV Buy
- Analyst Count
- OSTX 3
- ACRV 7
- Target Price
- OSTX $18.00
- ACRV $17.60
- AVG Volume (30 Days)
- OSTX 755.1K
- ACRV 283.2K
- Earning Date
- OSTX 08-14-2025
- ACRV 08-12-2025
- Dividend Yield
- OSTX N/A
- ACRV N/A
- EPS Growth
- OSTX N/A
- ACRV N/A
- EPS
- OSTX N/A
- ACRV N/A
- Revenue
- OSTX N/A
- ACRV N/A
- Revenue This Year
- OSTX N/A
- ACRV N/A
- Revenue Next Year
- OSTX N/A
- ACRV N/A
- P/E Ratio
- OSTX N/A
- ACRV N/A
- Revenue Growth
- OSTX N/A
- ACRV N/A
- 52 Week Low
- OSTX $1.12
- ACRV $1.05
- 52 Week High
- OSTX $7.00
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- OSTX N/A
- ACRV 61.12
- Support Level
- OSTX N/A
- ACRV $1.34
- Resistance Level
- OSTX N/A
- ACRV $1.48
- Average True Range (ATR)
- OSTX 0.00
- ACRV 0.08
- MACD
- OSTX 0.00
- ACRV 0.01
- Stochastic Oscillator
- OSTX 0.00
- ACRV 81.30
About OSTX OS THERAPIES INCORPORATED
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The companys mission is to address the need for new treatments in cancers of the bone in children and young adults.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.